Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
25.2M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
2.26M
-
Shares change
-
+2.06M
-
Total reported value, excl. options
-
$13M
-
Value change
-
+$12.1M
-
Number of buys
-
34
-
Number of sells
-
-2
-
Price
-
$5.75
Significant Holders of Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share (AXDX) as of Q3 2023
36 filings reported holding AXDX - Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share as of Q3 2023.
Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share (AXDX) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.26M shares
of 25.2M outstanding shares and own 8.97% of the company stock.
Largest 10 shareholders include GRIFFIN ASSET MANAGEMENT, INC. (1.18M shares), VANGUARD GROUP INC (303K shares), ORACLE INVESTMENT MANAGEMENT INC (137K shares), Alyeska Investment Group, L.P. (124K shares), Cannell & Co. (115K shares), GEODE CAPITAL MANAGEMENT, LLC (59K shares), TCI Wealth Advisors, Inc. (58.7K shares), BlackRock Inc. (50.8K shares), NORTHERN TRUST CORP (50.1K shares), and Cladis Investment Advisory, LLC (36.2K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.